Events

Research & Innovation for a Competitive Green Transition
JUN
Mon
23
JUN
Tue
24

This was 1 week ago

Location

Charlemagne Bulding

Charlemagne Bulding, Wetstraat 170, Brussel
Programmes
Climate, Energy, Mobility Agro-Food, Environment Green Deal

Taking place as a satellite event of the European Research and Innovation (R&I) Days 2025, the two-day conference, "R&I for a Competitive Green Transition," will showcase tangible solutions for Europe’s green transition. 

On the 23rd of June, there will be an exhibition in the late afternoon with an overview of 15 innovative projects that have been funded under the Horizon programmes and have made a contribution to the green transition. On the 24th, there is a full day of information sessions and keynote speeches. 

You can discover the full programme here.

 

 

 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.